Dipeptidyl peptidase-4 inhibitors (DPP-4i), as one of common antidiabetic reagents, are currently recommended for the first-line hypoglycemic treatment of type 2 diabetes mellitus (T2DM). Here, DPP4 is linked to type 2 diabetes mellitus.